Objective: To compare snoring levels, respiratory and cardiac events before and after the placement of a new mandibular advancement device (MAD) designed for snoring control, placed as an option for the control of pathological mechanisms respiratory disorders that have been associated with cognitive dysfunction, excessive daytime sleepiness and as an aggravator of the development of Alzheimer’s and Parkinson’s.
Methodology: Study of a case series that considered 12 snoring adults initially identified with the Roncolab® App. A clinical history of sleep and initial (A) and final (D) polysomnography (PSG) was performed. A new design of intra-oral mandibular advancement device for snoring control was placed, which was reviewed every 20 days for two months. Neurophysiological, cardio-pulmonary and sleep parameters were analyzed. The statistical differences between the variables were established according to the distribution of the data with tests of t-student or Mann-Whitney U.
Results: The average snoring events according to PSG were (A: 198; D: 260) with p> 0.05; according to Roncolab® (A: 73.6; D: 22.6) with a p <0.05. There were no differences between the oximetry averages (A: 0.84; D: 0.83) or heart rate (A: 65; D: 66.9).
Conclusions: There was no statistically significant difference in respiratory, cardiac events, oximetry nor apnea episodes according to PSG, after the placement of the manufactured DAM. Roncolab® registered a significant decrease in snoring events.
